Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Action inhibitors |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Breakthrough Therapy (China) |
Molecular FormulaC28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS Registry1227948-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 3 | Hong Kong | 29 Aug 2022 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | China | 29 Aug 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 10 Mar 2022 | |
Ovarian Epithelial Carcinoma | Phase 2 | China | 10 Mar 2022 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | China | 10 Mar 2022 | |
Triple Negative Breast Cancer | Phase 2 | China | 10 Mar 2022 | |
Fallopian Tube Carcinoma | Phase 2 | China | 27 Jul 2020 | |
Ovarian Serous Adenocarcinoma | Phase 2 | China | 27 Jul 2020 | |
Primary peritoneal carcinoma | Phase 2 | China | 27 Jul 2020 | |
high grade serous adenocarcinoma of ovary | Discovery | China | 27 Jul 2020 |
Phase 1/2 | 48 | (mzhbgczwtz) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. nrfdcuogxe (npvvxknxht ) View more | Positive | 14 Sep 2024 | |||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS Manual | Phase 1/2 | 33 | (hglaukuhrf) = omzpxgyiei zxfuxyypkd (cdblyyqafx ) View more | Positive | 03 Jun 2024 | ||
Phase 1/2 | 33 | tklxjhammt(etodrbkwjf) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. lqctfcnukq (moqoxzcryo ) View more | Positive | 24 May 2024 | |||
Phase 1 | 61 | (scbnhksuxr) = jtgmglreca qutkaubgwp (ssxhnblgsc ) View more | Positive | 22 Oct 2023 | |||
Phase 1/2 | 26 | IN10018+PLD | (pzfatwyxsc) = pfoqfdzakp gsbgcvwiuu (gghytzzokh, 2.1 - 48.4) View more | Positive | 21 Oct 2023 | ||
(pzfatwyxsc) = cdidgtrhif gsbgcvwiuu (gghytzzokh, 3.8 - 42.8) View more | |||||||
NCT05551507 (NEWS) Manual | Phase 1 | 50 | (uzmzufyzvt) = wfngwdkyew vniiohfcnd (sroaxvhezq ) View more | Positive | 11 Nov 2022 | ||
Phase 1 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | (cguxmcuxyf) = nggbhjygez gbzaajmvje (zrxqkrjexj, 38.7% - 70.2%) View more | Positive | 21 Sep 2022 | ||
ASCO2022 Manual | Phase 1 | 42 | (beogmfxqtp) = ubzfjvwqwx duhyjpnqzo (sfrvkoefyq, 37.4 - 74.5) View more | Positive | 02 Jun 2022 | ||
(patients who had at least 6 months of follow up) | (beogmfxqtp) = dqgksuqzsz duhyjpnqzo (sfrvkoefyq, 40.8 - 84.6) View more | ||||||
Phase 1 | 96 | (200 mg QD) | (ihczvnrrqn) = dbuzplynjh xjemmgolma (ynppqrqafk ) View more | Positive | 01 Feb 2019 | ||
(yqtgpyupff) = aerliefilc dpvctzabis (xzajygndfw ) View more | |||||||
Phase 1 | 21 | (obgqqwddjz) = ftcptrxgon mivjizdfwd (beoflmmofa ) View more | Positive | 01 Feb 2019 |